225 related articles for article (PubMed ID: 25769931)
1. Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor.
Bratcher PE; Rowe SM; Reeves G; Roberts T; Szul T; Harris WT; Tirouvanziam R; Gaggar A
J Cyst Fibros; 2016 Jan; 15(1):67-73. PubMed ID: 25769931
[TBL] [Abstract][Full Text] [Related]
2. Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.
Donaldson SH; Pilewski JM; Griese M; Cooke J; Viswanathan L; Tullis E; Davies JC; Lekstrom-Himes JA; Wang LT;
Am J Respir Crit Care Med; 2018 Jan; 197(2):214-224. PubMed ID: 28930490
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory microbiota composition.
Peleg AY; Choo JM; Langan KM; Edgeworth D; Keating D; Wilson J; Rogers GB; Kotsimbos T
J Cyst Fibros; 2018 Jan; 17(1):50-56. PubMed ID: 29042177
[TBL] [Abstract][Full Text] [Related]
4. GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1).
Davies JC; Van de Steen O; van Koningsbruggen-Rietschel S; Drevinek P; Derichs N; McKone EF; Kanters D; Allamassey L; Namour F; de Kock H; Conrath K
J Cyst Fibros; 2019 Sep; 18(5):693-699. PubMed ID: 31147302
[TBL] [Abstract][Full Text] [Related]
5. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.
Guerra L; D'Oria S; Favia M; Castellani S; Santostasi T; Polizzi AM; Mariggiò MA; Gallo C; Casavola V; Montemurro P; Leonetti G; Manca A; Conese M
Pediatr Pulmonol; 2017 Jul; 52(7):900-908. PubMed ID: 28445004
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
[TBL] [Abstract][Full Text] [Related]
8. A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation.
Davies JC; Sermet-Gaudelus I; Naehrlich L; Harris RS; Campbell D; Ahluwalia N; Short C; Haseltine E; Panorchan P; Saunders C; Owen CA; Wainwright CE;
J Cyst Fibros; 2021 Jan; 20(1):68-77. PubMed ID: 32967799
[TBL] [Abstract][Full Text] [Related]
9. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.
Kotha K; Clancy JP
Ther Adv Respir Dis; 2013 Oct; 7(5):288-96. PubMed ID: 24004658
[TBL] [Abstract][Full Text] [Related]
10. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
[TBL] [Abstract][Full Text] [Related]
11. A small molecule CFTR potentiator restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR.
Liu J; Berg AP; Wang Y; Jantarajit W; Sutcliffe KJ; Stevens EB; Cao L; Pregel MJ; Sheppard DN
Br J Pharmacol; 2022 Apr; 179(7):1319-1337. PubMed ID: 34644413
[TBL] [Abstract][Full Text] [Related]
12. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor.
Flume PA; Wainwright CE; Elizabeth Tullis D; Rodriguez S; Niknian M; Higgins M; Davies JC; Wagener JS
J Cyst Fibros; 2018 Jan; 17(1):83-88. PubMed ID: 28651844
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease.
Cho DY; Zhang S; Lazrak A; Grayson JW; Peña Garcia JA; Skinner DF; Lim DJ; Mackey C; Banks C; Matalon S; Woodworth BA
Int Forum Allergy Rhinol; 2019 Jan; 9(1):100-105. PubMed ID: 30152192
[TBL] [Abstract][Full Text] [Related]
14. [Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation].
Gomez-Pastrana D; Nwokoro C; McLean M; Brown S; Christiansen N; Pao CS
An Pediatr (Engl Ed); 2019 Mar; 90(3):148-156. PubMed ID: 30093322
[TBL] [Abstract][Full Text] [Related]
15. IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation.
van de Peppel IP; Doktorova M; Berkers G; de Jonge HR; Houwen RHJ; Verkade HJ; Jonker JW; Bodewes FAJA
J Cyst Fibros; 2019 Mar; 18(2):286-293. PubMed ID: 30279125
[TBL] [Abstract][Full Text] [Related]
16. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
17. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
[TBL] [Abstract][Full Text] [Related]
18. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
McPhail GL; Clancy JP
Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
[TBL] [Abstract][Full Text] [Related]
19. Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States.
Taylor-Cousar J; Niknian M; Gilmartin G; Pilewski JM;
J Cyst Fibros; 2016 Jan; 15(1):116-22. PubMed ID: 25682022
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.
Davies JC; Wainwright CE; Canny GJ; Chilvers MA; Howenstine MS; Munck A; Mainz JG; Rodriguez S; Li H; Yen K; Ordoñez CL; Ahrens R;
Am J Respir Crit Care Med; 2013 Jun; 187(11):1219-25. PubMed ID: 23590265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
